• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Can Viking Therapeutics stock retain today’s gains?

by September 22, 2026
written by September 22, 2026

Viking Therapeutics (VKTX) stock ripped higher on Tuesday morning after the biopharmaceutical company published promising clinical trial data.

Investors rallied around new Phase 2 top-line results for the firm’s flagship weight-loss candidate, VK2735, which showed patients can trim dosing frequency without sacrificing significant weight loss progress.

Note that Viking Therapeutics shares have been a volatile investment in 2026, now up nearly 10% versus their price at the start of this year, but down some 7% versus their July high.

What we know about Viking Therapeutics’ Phase 2 update

After an initial 21-week induction period where patients achieved between 16% and 19% weight reduction, Viking transitioned participants of its Phase 2 clinical trial to less frequent maintenance schedules.

Patients switched to an “every-other-week” regimen retained up to 97% of their initial weight loss over 12 weeks, while those placed on monthly dosing retained up to 90%.

Plus, an exploratory cohort continuing weekly 17.5 mg injections reached 22% placebo-adjusted weight loss by Week 33 without hitting a plateau.

VKTX shares are rallying because these results address one of the steepest operational bottlenecks in the anti-obesity drug landscape: patient adherence and treatment fatigue under weekly injection schedules.

Beyond demonstrating efficacy, VK2735 delivered a clean safety profile with gastrointestinal side effects comparable to placebo during maintenance, reinforcing its potential to rival “established” blockbusters like Lilly’s Zepbound and Novo’s Wegovy.

Is it already too late to invest in VKTX shares?

While the headline initially triggered aggressive buying, holding onto these substantial gains over the medium term depends on clinical execution and commercial strategy.

Clinical-stage biotechs frequently experience profit-taking selloffs following major trial readouts as momentum traders exit positions.

However, Viking Therapeutics stock has multiple “structural catalysts” that could help consolidate these gains.

Unlike single-shot clinical plays, the company is advancing both subcutaneous and oral iterations of VK2735, with Phase 3 VANQUISH trials already fully enrolled and an oral Phase 3 expected to initiate before year-end 2026.

If VKTX can successfully execute “Part 2” of its current study – testing oral maintenance options following injectable induction – it will establish a unique “shot-to-pill” treatment ladder that few competitors can replicate.

What to expect from Viking Therapeutics’ stock

Looking ahead, the long-term thesis for VKTX stock is rooted in whether the company intends to commercialize VK2735 independently or position itself for an acquisition by a big pharmaceutical conglomerate.

Navigating global supply chains and scaling production of GLP-1/GIP therapies requires billions in capital – a challenge that could strain Viking’s balance sheet as Phase 3 studies progress toward commercial filing.

Big pharma players seeking entry or expanded market share in the massive metabolic space view flexible-dosing assets as prime acquisition targets.

But if Viking decides to go at it alone, cash burn rates and future equity dilution remain legitimate risk factors for share retention.

That said, with promising clinical data backing its pipeline and a distinct competitive advantage in maintenance convenience, the biotech has firmly positioned itself as a pivotal force in the evolving obesity market.

The post Can Viking Therapeutics stock retain today’s gains? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
MAGS: Top Magnificent 7 ETF inflows surge as Meta, AAPL stocks surge
next post
Why has Berkshire Hathaway invested in this homebuilder’s stock

related articles

The complicated business of betting on Big Tech’s...

November 21, 2026

FT finds Alice Huang linked to chip network...

November 21, 2026

Is Nvidia’s Colette Kress standing on a glass...

November 21, 2026

Will Jensen Huang’s ouster push founders to secure...

November 21, 2026

Michael Burry takes profits on Nvidia puts as...

November 20, 2026

Why Intel shares are falling over 5% on...

November 20, 2026

PayPal stock falls 4% as leadership shake-up tests...

November 20, 2026

Evening digest: Anthropic slides after record debut, Bitcoin...

November 20, 2026

Why Broadcom shares are down over 11% on...

November 20, 2026

Why CoreWeave and Nebius stocks are falling on...

November 20, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Dow falls 350 points as 10 year Treasury yields hit 5.1%

    September 23, 2026
  • Here’s why IREN, CoreWeave, and Nebius stocks are in free fall

    July 17, 2026
  • Omar’s disclosures erased millions, leaving her with potential negative net worth. She won’t explain why

    July 9, 2026
  • Micron and SanDisk up nearly 2% premarket, but one risk is getting harder to ignore

    September 8, 2026
  • What’s the point of investing in Cathie Wood’s ARKK ETF anyway?

    June 25, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Dow rises 260 points as weak jobs data lifts US stocks

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,694)
  • Stock (90)

Latest Posts

  • Novo Nordisk CEO eyes M&A and a pill-led future after investor backlash

    September 22, 2026
  • Analyst explains what Strategy stock needs to stop the bleeding

    June 25, 2026
  • Palantir stock slips below a crucial technical price: here’s why

    June 18, 2026

Recent Posts

  • Neonatologist sounds alarm over Massachusetts abortion law allowing procedures up to birth: ‘Very disturbing’

    August 18, 2026
  • Dems join Republicans to crush Tlaib’s war powers resolution in lopsided House vote

    June 30, 2026
  • Robinhood stock rises as analysts see growth beyond its brokerage business

    October 21, 2026

Editor’s Pick

  • Zhipu stock surges 33% as Anthropic curbs open door for China AI

    June 15, 2026
  • Socialists launch radical platform to abolish the US Senate in bid to fundamentally transform America

    July 10, 2026
  • DRAM ETF falls 6.5% after Samsung earnings as expert warns on memory stocks

    July 7, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock